The Use of Andexanet Alfa in Hemorrhagic Stroke Patients and Aspirin's Effect on Liver Fat

The chapter delves into a study where patients with intracranial hemorrhage and without severe neurologic deficits were treated with Andexanet Alfa or usual care, exploring outcomes up to 30 days. It also discusses the use of aspirin in reducing hepatic fat in patients with liver disease, with insights from a positive trial and concerns about bias. The conversation includes considerations on reversal agents for DOACs and the implications of the evolving terminology around metabolic liver diseases.